Effectiveness Of Priority Review Voucher, Orphan Status Part Of Tropical Disease Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
September public hearing will continue FDA's look into rare and neglected disease drug development.
You may also be interested in...
FDA To Offer Reviewers Rare Disease Training; Patient Groups Want Separate ODE
FDA will offer training next year for reviewers to better understand rare diseases and their associated product applications that could help speed the approval process, although it appears to be optional.
FDA To Offer Reviewers Rare Disease Training; Patient Groups Want Separate ODE
FDA will offer training next year for reviewers to better understand rare diseases and their associated product applications that could help speed the approval process, although it appears to be optional.
Priority Review Voucher's Uncertain Value May Hinder Development
FDA’s innovative priority review voucher, intended to incentivize the development of new drugs for neglected diseases, may actually have created a hurdle in some cases.